Rubio-Guerra, S, Sala, I, Sánchez-Saudinos, MB, Videla, L, Bejanin, A, Estanga, A, Ecay-Torres, M, de Luis, CL, Rami, L, Tort-Merino, A, Castellví, M, Pozueta, A, García-Martínez, M, Gomez-Andrés, D, Lage, C, Lopez-García, S, Sánchez-Juan, P, Balasa, M, Llado, A, Altuna, M, Tainta, M, Arranz, J, Zhu, NL, Alcolea, D, Lleo, A, Fortea, J, Rodríguez, ER, Sánchez-Valle, R, Martínez-Lage, P, Illán-Gala, I. Amyloid-negative neuropsychological norms: Added value in the era of biomarkers and disease-modifying therapies. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring. 2025; 17(4)DOI:10.1002/dad2.70223. PMID:41383878. IF:(Q/D).

Rubio-Guerra, S, Sánchez-Saudinos, MB, Sala, I, Videla, L, Bejanin, A, Estanga, A, Ecay-Torres, M, de Luis, CL, Rami, L, Tort-Merino, A, Castellví, M, Pozueta, A, García-Martínez, M, Gomez-Andrés, D, Lage, C, Lopez-García, S, Sánchez-Juan, P, Balasa, M, Llado, A, Altuna, M, Tainta, M, Arranz, J, Zhu, NL, Alcolea, D, Lleo, A, Fortea, J, Rodríguez, ER, Sánchez-Valle, R, Martínez-Lage, P, Illán-Gala, I. Development of amyloid-negative neuropsychological norms using GAMLSS. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring. 2025; 17(4)DOI:10.1002/dad2.70224. PMID:41383879. IF:(Q/D).

Andersen, OM, de Waal, MWJ, Monti, G, Tesi, N, Jensen, AMG, De Geus, C, van Spaendonk, R, Vogel, M, Ahmad, S, Amin, N, Amouyel, P, Beecham, GW, Bellenguez, C, Berr, C, Bis, JC, Boland, A, Bossù, P, Bouwman, F, Bras, J, Charbonnier, C, Clarimon, J, Cruchaga, C, Daniele, A, Dartigues, JF, Debette, S, Deleuze, JF, Denning, N, Destefano, AL, Dols-Icardo, O, van Duijn, CM, Farrer, LA, Fernández, MV, van der Flier, WM, Fox, NC, Galimberti, D, Genin, E, Gille, JJP, Grenier-Boley, B, Grozeva, D, Guen, YL, Guerreiro, R, Haines, JL, Holmes, C, Hummerich, H, Ikram, MA, Ikram, MK, Kawalia, A, Kraaij, R, Lambert, JC, Lathrop, M, Lemstra, AW, Lleo, A, Myers, RM, Mannens, MMAM, Marshall, R, Martin, ER, Masullo, C, Mayeux, R, Mead, S, Mecocci, P, Meggy, A, Mol, MO, Nacmias, B, Naj, AC, Napolioni, V, Cochran, JN, Nicolas, G, Pasquier, F, Pastor, P, Pericak-Vance, MA, Pijnenburg, YAL, Piras, F, Quenez, O, Ramirez, A, Raybould, R, Redon, R, Reinders, MJT, Richard, AC, Riedel-Heller, SG, Rivadeneira, F, van Rooij, JGJ, Rousseau, S, Ryan, NS, Sanchez-Juan, P, Schellenberg, GD, Scheltens, P, Schott, JM, Seshadri, S, Sie, D, Sims, R, Sistermans, EA, Sorbi, S, van Swieten, JC, Tijms, B, Uitterlinden, AG, Visser, PJ, Wagner, M, Wallon, D, Wang, LS, Williams, J, Yokoyama, JS, Zarea, A, van der Lee, SJ, Olsen, JG, Hulsman, M, Holstege, H. Domain mapping of disease mutations reveals pathogenic SORL1 variants in Alzheimer's disease. Molecular Neurodegeneration. 2025; 20(1)DOI:10.1186/s13024-025-00907-z. PMID:41327266. IF:17.500(Q1/1D).

Barba, L, Bellomo, G, Alcolea, D, Wojdala, AL, Gaetani, L, Fortea, J, Abu-Rumeileh, S, Lleó, A, Parnetti, L, Belbin, O, Otto, M, Oeckl, P. Serum level changes of the synaptic marker beta-synuclein in Alzheimer's disease continuum and other dementias. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. 2025; 96(12)DOI:10.1136/jnnp-2025-336189. PMID:40571405. IF:7.500(Q1/1D).

Muñoz-Vendrell, A, Campoy-Díaz, S, Valín-Villanueva, P, Casas-Limón, J, Fernández-Lázaro, I, González-García, N, Santos-Lasaosa, S, Osorio, YG, Gonzalez-Martinez, A, Campdelacreu, J, Portocarrero-Sánchez, L, Sánchez, LMC, Sánchez, SMG, Pérez-de-la-parte, A, Sánchez-Mateos, NM, López-Bravo, A, Mínguez-Olaondo, A, Sánchez-Soblechero, A, Ros, AL, Hernández, CM, López, AA, Layos-Romero, A, Caronna, E, Torres-Ferrús, M, Alpuente, A, Pozo-Rosich, P, Belvís, R, Garcia-Azorin, D, Díaz-de-Terán, J, Guerrero-Peral, AL, Gago-Veiga, AB, Huerta-Villanueva, M. Atogepant after anti-CGRP monoclonal antibodies failure in migraine: a multicenter real-world study of effectiveness, safety, persistence and predictors of response. JOURNAL OF HEADACHE AND PAIN. 2025; 27(1)DOI:10.1186/s10194-025-02239-1. PMID:41315923. IF:7.900(Q1/1D).

Huber, H, Arranz, J, Arslan, B, Leuzy, A, Kittel, O, Di Molfetta, G, Benejam, B, Videla, L, Barroeta, I, Soriano, LD, Maure-Blesa, L, Rodríguez-Baz, I, Infante, JEA, Illán-Gala, I, Bejanin, A, Montoliu-Gaya, L, Lleo, A, Carmona-Iragui, M, Alcolea, D, Blennow, K, Zetterberg, H, Fortea, J, Ashton, NJ. Plasma p-tau217 as a biomarker of Alzheimer's disease pathology in individuals with Down syndrome. Nature Communications. 2025; 16(1)DOI:10.1038/s41467-025-65882-x. PMID:41213934. IF:15.700(Q1/1D).